Table 1.
Clinical characteristics of patients.
| N | % | ||
|---|---|---|---|
| Gender | Male | 25 | 50 |
| Female | 25 | 50 | |
| Age | Median (range) | 60.5 (33–76) years | |
| ECOG PS | 0 | 34 | 68 |
| 1 | 16 | 32 | |
| Chemotherapy | FOLFIRINOX | 16 | 32 |
| GEMnPAC | 34 | 68 | |
| Stage | III | 16 | 32 |
| IV | 34 | 68 | |
| Primary tumor location | Head | 23 | 46 |
| Body-tail | 27 | 54 | |
| Number of metastatic sites | 1–2 | 36 | 72 |
| 3–5 | 14 | 28 | |
| Liver metastases | No | 16 | 32 |
| Yes | 21 | 42 | |
| NA | 13 | 26 | |
| Lung metastases | No | 28 | 56 |
| Yes | 9 | 18 | |
| NA | 13 | 26 | |
| Baseline CA 19-9 (U/mL) | median (range) | 266.6 (0.1–120,000) | |
| ≤median | 25 | 50 | |
| >median | 24 | 48 | |
| NA | 1 | 2 | |
| Baseline NLR | median (range) | 2.21 (0.538–9.46) | |
| ≤median | 24 | 48 | |
| >median | 23 | 46 | |
| NA | 3 | 6 | |
| Baseline PLR | median (range) | 128.99 (60.76–409.9) | |
| ≤median | 24 | 48 | |
| >median | 23 | 46 | |
| NA | 3 | 6 | |
| PD-L1 mRNA at baseline (%FA) | Negative | 22 | 44 |
| Positive | 28 | 56 | |
| PD-L1 mRNA at 3 months (%FA) | Negative | 11 | 22 |
| Positive | 38 | 76 | |
| NA | 1 | 2 |
Abbreviations: N, number; ECOG PS, Eastern Cooperative Oncology Group performance status; GEMnPAC, gemcitabine plus nab-paclitaxel; FOLFIRINOX, 5-FU, irinotecan, and oxaliplatin; CA 19-9, carbohydrate antigen 19-9; NA, not available; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; PD-L1, programmed death-ligand 1; FA, fractional abundance.